Skip to content

Effects of food containing Kurozu Moromi and garlic powder on immune function : a randomized, double blind, placebo-controlled study

Effects of food containing Kurozu Moromi and garlic powder on immune function : a randomized, double blind, placebo-controlled study - Effects of food containing Kurozu Moromi and garlic powder on immune function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013933
Enrollment
60
Registered
2014-05-12
Start date
2014-05-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Ingestion of food containing Kurozu Moromi and garlic powder for 8 consecutive weeks Ingestion of placebo (food without Kurozu Moromi and garlic powder) for 8 consecutive weeks

Sponsors

TTC Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) An age 30 years or older and up to 60 years 2) A lower salivary secretory immunoglobulin A secretion rate

Exclusion criteria

Exclusion criteria: 1) Subjects who consume food containing Kurozu Moromi and garlic 2) Subjects routinely taking dietary supplements which may influence immune function 3) Subjects who has history of the allergic disease 4) Subjects who are under medication (e.g., hyposensitization) which may influence the outcome of the study 5) Subjects who are have treated oral or dental care within the last one month prior to the current study or are planned to treat oral or dental care 6) Subjects who has oral or dental problems with bleeding 7) Night and day shift worker or manual laborer 8) Subjects who has carries out an intense activity (e.g., marathon race) 9) Subjects who cannot carry out a procedure of various inspection by the rule during the study period 10) Subjects who has a disease under treatment or are judged to that medical treatment are necessary by the doctor 11) Subjects who has under treatment or a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease) and disease to affect the adrenal cortical hormone secretion 12) Subjects with allergies to the products used in the study 13) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination 14) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating 15) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study 16) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire 17) Subjects who are judged as unsuitable for the study by the investigator for other reason

Design outcomes

Primary

MeasureTime frame
Immune function (salivary sIgA secretion rate, CD4, CD8, CD4/CD8 ratio)

Secondary

MeasureTime frame
cytokine

Countries

Japan

Contacts

Public ContactHiroyasu Shimada

TTC Co., Ltd. Clinical Research Planning Department

ttcpwr2001@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026